Evidence map›Paper›PMID 34410327›Full record

ArticleThe Journal of experimental medicine2021

Surmounting structural barriers to tackle endemic infectious diseases.

Felix Calderón, Alan H Fairlamb, Mike Strange, Pauline Williams, Carl F Nathan

Abstract read
In one paragraph

Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Felix CalderónGlobal Health Pharma Unit, GlaxoSmithKline R&D, Tres Cantos, Madrid, Spain.ORCID 0000-0003-0486-6883
Alan H FairlambDivision of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee, UK.ORCID 0000-0001-5134-0329
Mike StrangeGlobal Health Pharma Unit, GlaxoSmithKline R&D, Tres Cantos, Madrid, Spain.
Pauline WilliamsGlobal Health Pharma Unit, GlaxoSmithKline R&D, Tres Cantos, Madrid, Spain.ORCID 0000-0001-9906-6226
Carl F NathanDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, NY.ORCID 0000-0002-7744-8896

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A unique experiment in bringing academic and industrial scientists together to tackle endemic infectious diseases has proved a success. The Tres Cantos Open Lab Foundation, guided and advised by independent experts, funds extended stays of academics at the campus of a pharmaceutical company, where they access the firm's resources in partnership with company scientists. Progress in tackling tuberculosis, protozoal infections, and enteric bacterial diseases has sustained the decade-long evolution of the model, whose distinctive features complement other public-private partnerships with similar goals.

Indexed as

Endemic DiseasesAcademies and InstitutesCommunicable DiseasesDrug DevelopmentDrug IndustryHumansPublic-Private Sector Partnerships

Identifiers

PMID34410327
PMCPMC8383816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.